Xylazine, a potent α₂-adrenergic receptor agonist and structural analog of clonidine, is a widely used veterinary drug—best known under brand names like Rompun (Bayer), Anased, Sedazine, and Chanazine. While critical for animal care, it has emerged as a dangerous street drug in recent years, raising major public health alarms.

Key Uses of Xylazine (Veterinary Context)

Xylazine is a staple in veterinary medicine for:

• Sedation, anesthesia, and muscle relaxation in large mammals (horses, cattle, etc.)
• Pain management (analgesia) during veterinary procedures
• Combining with other agents for surgical anesthesia in animals

Veterinarians also use it to reverse certain drug interactions, though its effects vary by species.

Xylazine’s Mechanism & History

First developed as a potential human antihypertensive, xylazine was repurposed for veterinary use after its sedative properties were identified in 1981. This discovery led to the creation of related α₂-agonists like medetomidine and dexmedetomidine.

Xylazine Abuse: “Tranq” and Public Health Risks

A growing crisis in the United States, xylazine is illicitly sold as “tranq” (a street name) and often mixed with opioids (e.g., fentanyl). Key risks of xylazine abuse in humans include:

• Severe sedation and respiratory depression
• Skin necrosis (painful, slow-healing wounds)
• Overdose risk (xylazine does not respond to naloxone, the opioid overdose reversal drug)
• Addiction and withdrawal symptoms

Key Takeaways

Xylazine remains essential for veterinary care but poses grave risks when misused. Public health efforts now focus on raising awareness of “tranq” and expanding treatment for xylazine-related harm.